Lay statement: Visceral leishmaniasis (VL) is a parasitic disease that is fatal if untreated. Several hundred thousand people are affected in the Indian subcontinent. Most are poor and depend on public funds or charity for treatment. Disease control is based on early diagnosis and treatment, and control of sandflies that transmit disease. Control efforts to date have given only temporary reprieve, with periodic rebound of major epidemics. This is because there are gaps in our understanding of the dynamics of disease transmission. This study is designed to identify these factors, and to evaluate novel diagnostics and vaccine candidates that have arisen through genomic sequencing of the parasite. The study will provide new knowledge and tools to allow regional governments to achieve their aim of disease control by 2015. Project description: VL in India is patchy in distribution. The determinants of disease transmission at a village and household level are not well understood. Subclinical infection is thought to play a significant role in disease transmission, but markers of subclinical infection have yet to be validated. We don't fully understand why only a small proportion of infected subjects develop clinical disease. To gain a better understanding of disease dynamics and transmission, this study will undertake (1) an exhaustive population survey of 50,000 persons for two consecutive years using household interviews, CIS technology, remote sensing data and multi-level modelling, to identify the ecological risk markers that will permit better targeting of control interventions;(2) a nested case control study to document the modifiable risk factors (e.g. nutritional) and risk markers (clinical, genetic, immunological) for VL at household and individual level, with two annual rounds of sero-survey allowing us to document incident leishmanial infections, and a 3-year longitudinal follow-up to document development of full blown VL;(3) evaluation of existing (rK39 ELISA, Direct Agglutination Test, LST) markers of infection against standard Western blot and qualitative kDNA PCR and new Quantiferon assays for T cell responses;(4) evaluation of novel (Leishmania donovani- complex specific genes) markers using qualitative and quantitative PCR, ELISA and T-cell assays;and (5) immune profiling of novel vaccine candidate in patients and endemic controls. The results will inform policy and practice for disease control in the Indian sub-continant, and add to global understanding of VL disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center (P50)
Project #
5P50AI074321-05
Application #
8319237
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
5
Fiscal Year
2011
Total Cost
$251,189
Indirect Cost
Name
Banaras Hindu University
Department
Type
DUNS #
650330558
City
Varanasi
State
Country
India
Zip Code
22100-5
Singh, Neetu; Sundar, Shyam (2018) Combined neutralization of interferon gamma and tumor necrosis factor alpha induces IL-4 production but has no direct additive impact on parasite burden in splenic cultures of human visceral leishmaniasis. PLoS One 13:e0199817
Singh, Neetu; Kumar, Rajiv; Chauhan, Shashi Bhushan et al. (2018) Peripheral Blood Monocytes With an Antiinflammatory Phenotype Display Limited Phagocytosis and Oxidative Burst in Patients With Visceral Leishmaniasis. J Infect Dis 218:1130-1141
Singh, Toolika; Fakiola, Michaela; Oommen, Joyce et al. (2018) Epitope-Binding Characteristics for Risk versus Protective DRB1 Alleles for Visceral Leishmaniasis. J Immunol 200:2727-2737
Sundar, Shyam; Singh, Anup (2018) Chemotherapeutics of visceral leishmaniasis: present and future developments. Parasitology 145:481-489
Sundar, Shyam; Singh, Bhawana (2018) Emerging therapeutic targets for treatment of leishmaniasis. Expert Opin Ther Targets 22:467-486
Sundar, Shyam; Singh, Bhawana (2018) Understanding Leishmania parasites through proteomics and implications for the clinic. Expert Rev Proteomics 15:371-390
Sundar, Shyam; Agarwal, Dipti (2018) Visceral Leishmaniasis-Optimum Treatment Options in Children. Pediatr Infect Dis J 37:492-494
Kelly, Patrick H; Bahr, Sarah M; Serafim, Tiago D et al. (2017) The Gut Microbiome of the Vector Lutzomyia longipalpis Is Essential for Survival of Leishmania infantum. MBio 8:
Sharma, Smriti; Srivastva, Shweta; Davis, Richard E et al. (2017) The Phenotype of Circulating Neutrophils during Visceral Leishmaniasis. Am J Trop Med Hyg 97:767-770
Kansal, S; Chakravarty, J; Kumar, A et al. (2017) Risk Factors associated with defaulting from visceral leishmaniasis treatment: analysis under routine programme conditions in Bihar, India. Trop Med Int Health 22:1037-1042

Showing the most recent 10 out of 90 publications